Center-Authored Papers

Filters: Author is Meshinchi, Soheil  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery DM et al..  2008.  Identification of genes with abnormal expression changes in acute myeloid leukemia.. Genes, chromosomes & cancer. 47(1):8-20. Abstract
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland GD, Radich JP.  2008.  Structural and numerical variation of FLT3/ITD in pediatric AML.. Blood. 111(10):4930-3. Abstract
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ et al..  2008.  DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 22(2):265-72. Abstract
2009
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2009.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 113(26):6558-66. Abstract
Meshinchi S, Appelbaum FR.  2009.  Structural and functional alterations of FLT3 in acute myeloid leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13):4263-9. Abstract
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H et al..  2009.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.. British journal of haematology. 144(3):388-94. Abstract
2010
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler VG et al..  2010.  Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(5):909-13. Abstract
Stirewalt DL, Meshinchi S.  2010.  Receptor tyrosine kinase alterations in AML - biology and therapy.. Cancer treatment and research. 145:85-108. Abstract
Radhi M, Meshinchi S, Gamis A.  2010.  Prognostic factors in pediatric acute myeloid leukemia.. Current hematologic malignancy reports. 5(4):200-6. Abstract
Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK et al..  2010.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.. Blood. 116(25):5638-49. Abstract
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman PW, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X et al..  2010.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.. The lancet oncology. 11(6):543-52. Abstract
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM.  2010.  MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 55(2):248-53. Abstract
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B et al..  2010.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 116(5):702-10. Abstract
2011
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
Pui C-H, Carroll WL, Meshinchi S, Arceci RJ.  2011.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(5):551-65. Abstract
Berman JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2011.  Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 25(6):1039-42.
Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.  2011.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(2):204-9. Abstract
2012
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS et al..  2012.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.. Blood. Abstract
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ et al..  2012.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group.. Cancer. 118(3):761-769. Abstract
Carpenter PA, Meshinchi S, Davies SM.  2012.  Transplantation for AML in children.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1 Suppl):S33-9.
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al..  2012.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.. Blood. 119(16):3705-11. Abstract
Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup MJ.  2012.  Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(6):1547-54. Abstract
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract